Clinical Trial Update: Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63 [Phase 1]

View source ↗

Summary

Phase 1 safety study of a nasal HIV vaccine adjuvanted with LTK63 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Nasal HIV vaccine adjuvanted with LTK63

Snippet

Sponsor: St George's, University of London | Conditions: HIV Infections | Phase 1 | Status: TERMINATED